AVE:
Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD
Absorption
Highlights:
• Avecho has today provided an update on its Australian Phase I PK study (‘the Study’),
announcing enrolment of the first healthy volunteers for the Study.
• The Study characterises the absorption profile of cannabidiol (CBD) from Avecho’s CBD softgel product, at two separate doses.
• The Study aims to recruit a total of 16 healthy volunteers in Australia, with dosing scheduled
to commence next month.
• Results from the Study are expected in Q4 2021.
Avecho CEO, Dr Paul Gavin, said: “We are delighted to progress enrolment of healthy volunteers
for this Study, and to commence formal clinical assessment of Avecho’s CBD soft-gel product. We
have invested time this year with Catalent further optimising and completing the product. Catalent
is a respected global leader in the development of drug technologies and we believe that the
collaboration and additional effort will ensure the dosage form reflects the highest possible standard.
We are excited to see how it performs in human studies.”
one for the watchlist, I think.
for more info. refer to todays ann.
- Forums
- ASX - Short Term Trading
- Short Term Trading Week Starting: 13 Sep
Short Term Trading Week Starting: 13 Sep, page-71
-
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online